Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026

Same author

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Blood neoplasia·2026

Same author

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Blood advances·2026

Same author

DDX41-Mutated AML: A Case Report and Perspectives.

JCO precision oncology·2026

Same author

CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia.

Cell reports. Medicine·2025

Same author

The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.

Frontiers in immunology·2025

Search research articles

Related Experiment Video

Updated: May 15, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

HitWalker: variant prioritization for personalized functional cancer genomics.

Daniel Bottomly¹, Beth Wilmot, Jeffrey W Tyner

¹Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA. bottomly@ohsu.edu

Bioinformatics (Oxford, England)

|January 11, 2013

Summary

HitWalker prioritizes cancer variants by integrating genomic data with functional assays. This computational tool aids in identifying oncogenic targets and visualizing results for personalized cancer therapy development.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Experiment Videos

Last Updated: May 15, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Area of Science:

Genomics
Bioinformatics
Cancer Research

Background:

Identifying the functional significance of genetic variations in cancer is crucial for developing targeted therapies.
Integrating genomic data with functional analyses is necessary to pinpoint oncogenic drivers.
Computational tools are needed to prioritize and visualize complex datasets for cancer variant interpretation.

Purpose of the Study:

To introduce HitWalker, a novel computational framework for prioritizing cancer-associated sequence variants.
To demonstrate HitWalker's ability to integrate diverse data types for enhanced variant analysis.
To provide an intuitive visualization method for biological interpretation of prioritized variants.

Main Methods:

HitWalker prioritizes patient variants based on their proximity to functional assay results within a protein-protein interaction network.
The framework is designed for extensibility, accommodating various data types to refine variant prioritization.
A shortest path-based visualization approach is employed for intuitive biological interpretation.

Main Results:

HitWalker provides a ranked list of prioritized cancer variants.
The tool facilitates the integration of genomic and functional data for mechanistic understanding.
Visualization aids in the biological interpretation of variant relevance.

Conclusions:

HitWalker is a valuable computational tool for determining the functional relevance of cancer variants.
The prioritization and visualization capabilities of HitWalker support the development of personalized cancer therapies.
Integrating diverse data types through HitWalker enhances the identification of oncogenic targets.